1. How many patients were treated, in the last 3 months available for moderate or severe atopic dermatitis ?
Of these treated patients how many are paediatric?
Between May 2019 and July 2019 there were 73 patients admitted with moderate or severe atopic dermatitis over the age of 18.
There were 15 patients admitted aged between 0 and 17.
Our data systems do not capture the level of required detail to say how many of these people were treated and would require a manual case note audit of all patients within this period. In this instance it will cost more than the appropriate limit to consider your request. The appropriate limit is specified in regulations and for the Trust this is set at £450. This represents the estimated cost of one person spending 2½ working days in determining whether the Trust holds the information, and locating, retrieving and extracting the information. Consequently the Trust is not obliged under Section 12 of the Freedom of Information Act 2000 to respond to your request and we will not be processing your request further.
2. How many patients were treated, in the last 3 months available for moderate or severe atopic dermatitis with the following drugs?
Acitretin 123
Alitretinoin 14
Pimecrolimus 18
Tacrolimus 52
Dupilumab [Dupixent] 25
Etanercept 12
Infliximab 171
Adalimumab 125
Ustekinumab 65
Please note, the above information is the number of times this drug has been prescribed. Patients may have been prescribed the drug more than once at different clinics/appointments.
3. How many patients aged 18 and over, were treated in the last 3 months available for asthma ?
Between May 2019 and July 2019 there were 4317 patients admitted with primary or secondary diagnosis of asthmas over the age of 18.
Our data systems do not capture this level of detail and would require a manual case note audit of all patients within this period. In this instance it will cost more than the appropriate limit to consider your request. The appropriate limit is specified in regulations and for the Trust this is set at £450. This represents the estimated cost of one person spending 2½ working days in determining whether the Trust holds the information, and locating, retrieving and extracting the information. Consequently the Trust is not obliged under Section 12 of the Freedom of Information Act 2000 to respond to your request and we will not be processing your request further.
If you narrow the scope of your request the Trust may be able to provide the information free of charge because it would costs less than the appropriate limit to do so, although I cannot guarantee that this will be the case. Any reformulated request I receive will be treated as a fresh FOI request.
4. How many patients aged 17 and under, were treated in the last 3 months available for asthma ?
Between May 2019 and July 2019 there were 381 patients admitted with primary or secondary diagnosis of asthmas between the age of 0 and 17.
Our data systems do not capture this level of detail and would require a manual case note audit of all patients within this period. In this instance it will cost more than the appropriate limit to consider your request. The appropriate limit is specified in regulations and for the Trust this is set at £450. This represents the estimated cost of one person spending 2½ working days in determining whether the Trust holds the information, and locating, retrieving and extracting the information. Consequently the Trust is not obliged under Section 12 of the Freedom of Information Act 2000 to respond to your request and we will not be processing your request further.
If you narrow the scope of your request the Trust may be able to provide the information free of charge because it would costs less than the appropriate limit to do so, although I cannot guarantee that this will be the case. Any reformulated request I receive will be treated as a fresh FOI request.
5. How many asthma patients were treated in the last 3 months available with:
Omalizumab [Xolair] 27
Mepolizumab [Nucala] 0
Reslizumab [Cinqaero] 0
Benralizumab [Fasenra] 0
Please note, the above information is the number of times this drug has been prescribed. Patients may have been prescribed the drug more than once at different clinics/appointments.
6. How many paediatric severe asthma patients have been treated with Xolair/omalizumab in the last 3 months available? This information is not available
7. How many chronic spontaneous urticaria (CSU) patients have been treated with Xolair/omalizumab in the last 3 months available? This information is not available